H-YAR^AAARQARAKALARQLGVAA-NH2

Ref. 3D-PP41815

Product Information

• Name: H-YAR^AAARQARAKALARQLGVAA-NH2

Description

Peptide H-YAR^AAARQARAKALARQLGVAA-NH2 is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-YAR^AAARQARAKALARQLGVAA-NH2 include the following: MMI-0100 ameliorates dextran sulfate sodium-induced colitis in mice through targeting MK2 pathway Z Wang, XY Liang, X Chang, YY Nie, C Guo, JH Jiang - Molecules, 2019 - mdpi.comhttps://www.mdpi.com/1420-3049/24/15/2832 Targeting the TGF-beta signaling pathway for fibrosis therapy: a patent review (2015-2020) X Li, Z Ding, Z Wu, Y Xu, H Yao - Expert Opinion on , 2021 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1080/13543776.2021.1896705 Thermosensitive Polymeric Nanoparticles for Drug Co-Encapsulation and Breast Cancer Treatment VFC Dartora , JS Passos , LV Costa-Lotufo , LB Lopes - Pharmaceutics, 2024 - mdpi.comhttps://www.mdpi.com/1999-4923/16/2/231 Peptide-mediated inhibition of mitogen-activated protein kinase-activated protein kinase-2 ameliorates bleomycin-induced pulmonary fibrosis R Vittal, A Fisher, H Gu, EA Mickler - American journal of , 2013 - atsjournals.orghttps://www.atsjournals.org/doi/abs/10.1165/rcmb.2012-0389OC Inhibition of mitogen-activated protein kinase (MAPK)-activated protein kinase 2 (MK2) is protective in pulmonary hypertension M Shafiq , K Jagavelu, H Iqbal , P Yadav , D Chanda - , 2021 - Am Heart Assochttps://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.120.15229 Targeting mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2, MK2): medicinal chemistry efforts to lead small molecule inhibitors to clinical trials M Fiore, S Forli , F Manetti - Journal of medicinal chemistry, 2016 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.5b01457 MMI-0100 inhibits cardiac fibrosis in myocardial infarction by direct actions on cardiomyocytes and fibroblasts via MK2 inhibition L Xu, CC Yates , P Lockyer , L Xie, A Bevilacqua - Journal of molecular and , 2014 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0022282814002922 Therapeutic MK2 inhibition blocks pathological vascular smooth muscle cell phenotype switch JW Tierney , BC Evans, J Cheung-Flynn, B Wang - JCI insight, 2021 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525639/ Matrix stiffness affects endocytic uptake of MK2-inhibitor peptides JL Brugnano, A Panitch - PLoS One, 2014 - journals.plos.orghttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0084821 Intranasal MMI-0100 Attenuates Abeta1−42- and LPS-Induced Neuroinflammation and Memory Impairments via the MK2 Signaling Pathway JH Jiang, Z Wang, XY Liang, YY Nie, X Chang - Frontiers in , 2019 - frontiersin.orghttps://www.frontiersin.org/articles/10.3389/fimmu.2019.02707/full Development of a novel cell-permeant peptide-based inhibitor of MAPKAP-K2 and application of this therapeutic to abdominal adhesion prevention BC Ward - 2009 - search.proquest.comhttps://search.proquest.com/openview/641c7481c93b26f443d0aaa475a7984f/1?pq-origsite=gscholar&cbl=18750 In-vitro smooth muscle-endothelial cell coculture to characterize cardiovascular therapeutics AK Ramaswamy - 2013 - search.proquest.comhttps://search.proquest.com/openview/d08cc2433a391cdee6c92f3a8f41bf8a/1?pq-origsite=gscholar&cbl=18750 Matrix Stiffness Affects Endocytic Uptake of MK2-Inhibitor Peptides A Panitch - 2014 - Citeseerhttps://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=dc65feaddcbf9ab0a1b65739494f8e54bcbfd457

• Brand: Biosynth